Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Three key modifications optimize its pharmacokinetics: Aib substitution at position 2 resists DPP-4 cleavage C18 fatty diacid via a hydrophilic linker at Lys26 enables strong, non-covalent albumin binding Arg substitution at position 34 prevents fatty acid binding at the wrong site These modifications produce a half-life of approximately 165 hours (7 days), enabling true once-weekly pharmacokinetics without microsphere encapsulation, plus a daily oral formulation (Rybelsus) using the SNAC absorption enhancer
Food and Drug Administration (FDA) for the diagnosis, treatment, cure, or prevention of any disease
Further research will be crucial in defining the optimal use, safety, and full spectrum of benefits of this combination therapy in various populations
C Toxicol
Thus, every site where LAs are used in potentially toxic doses should be equipped with basic resuscitation equipment and a 20% lipid emulsion
Kidney Int 98:769777
US$ 28.78
US$ 22.91
US$ 23.69
US$ 23.78
US$ 22.12
US$ 22.06
US$ 28.50
US$ 20.95
